3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
2
Thoracic
1
Plasma cell
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Conditions
Ovarian Neoplasms
7
Colorectal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Pancreatic Neoplasms
2
Neoplasms by Site
2
Neoplasms
2
Melanoma
2
Fallopian Tube Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Thoracic Neoplasms
1
Skin Neoplasms
1
Sarcoma
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Prostatic Neoplasms
1
Noonan Syndrome
1
Neoplasms, Squamous Cell
1
Neoplasms by Histologic Type
1
Multiple Myeloma
1
Lung Neoplasms
1
Lung Diseases
1
Laryngeal Neoplasms
1
Hematologic Neoplasms
1
Glioma
1
Glioblastoma
1
Interventions
anlotinib
2
Bevacizumab
2
trametinib
1
siltuximab
1
olaparib
1
niraparib
1
enzalutamide
1
dabrafenib
1
cobimetinib
1
atezolizumab
1
Vemurafenib
1
Papanicolaou Test
1
Human Papillomavirus DNA Tests
1
Drug Therapy
1
Colposcopy
1
CP protocol
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms by Histologic Type
×
cobimetinib
×
Gynecologic
×
Clear all
NCT05768178
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled